Ultrafine particles affect the balance of endogenous pro- and anti-inflammatory lipid mediators in the lung: in-vitro and in-vivo studies

BackgroundExposure to ultrafine particles exerts diverse harmful effects including aggravation of pulmonary diseases like asthma. Recently we demonstrated in a mouse model for allergic airway inflammation that particle-derived oxidative stress plays a crucial role during augmentation of allergen-induced lung inflammation by ultrafine carbon particle (UfCP) inhalation. The mechanisms how particle inhalation might change the inflammatory balance in the lungs, leading to accelerated inflammatory reactions, remain unclear. Lipid mediators, known to be immediately generated in response to tissue injury, might be strong candidates for priming this particle-triggered change of the inflammatory balance.MethodsWe hypothesize that inhalation of UfCP may disturb the balance of pro- and anti-inflammatory lipid mediators in: i) a model for acute allergic pulmonary inflammation, exposing mice for 24 h before allergen challenge to UfCP inhalation (51.7 nm, 507 μg/m3), and ii) an in-vitro model with primary rat alveolar macrophages (AM) incubated with UfCP (10 μg/1 x 106 cells/ml) for 1 h. Lungs and AM were analysed for pro- and anti-inflammatory lipid mediators, namely leukotriene B4 (LTB4), prostaglandin E2 (PGE2), 15(S)-hydroxy-eicosatetraenoic acid (15(S)-HETE), lipoxin A4 (LXA4) and oxidative stress marker 8-isoprostane by enzyme immunoassays and immunohistochemistry.ResultsIn non-sensitized mice UfCP exposure induced a light non-significant increase of all lipid mediators. Similarly but significantly in rat AM all lipid mediators were induced already within 1 h of UfCP stimulation. Also sensitized and challenge mice exposed to filtered air showed a partially significant increase in all lipid mediators. In sensitized and challenged mice UfCP exposure induced highest significant levels of all lipid mediators in the lungs together with the peak of allergic airway inflammation on day 7 after UfCP inhalation. The levels of LTB4, 8-isoprostane and PGE2 were significantly increased also one day after UfCP exposure. Immunohistochemistry localized highest concentrations of PGE2 especially in AM one day after UfCP exposure.ConclusionOur results suggest that UfCP exposure affects the balance between pro- and anti-inflammatory lipid mediators. In allergic mice, where the endogenous balance of pro- and anti-inflammatory mediators is already altered, UfCP exposure aggravates the inflammation and the increase in anti-inflammatory, pro-resolving lipid mediators is insufficient to counterbalance the extensive inflammatory response. This may be a contributing mechanism that explains the increased susceptibility of asthmatic patients towards particle exposure.

[1]  H. Schulz,et al.  Role of oxidative stress in ultrafine particle-induced exacerbation of allergic lung inflammation. , 2009, American journal of respiratory and critical care medicine.

[2]  J. Crapo,et al.  Allometric relationships of cell numbers and size in the mammalian lung. , 1992, American journal of respiratory cell and molecular biology.

[3]  C. Pope,et al.  Health effects of particulate air pollution: time for reassessment? , 1995, Environmental health perspectives.

[4]  W. Busse,et al.  Airway lipoxin A4 generation and lipoxin A4 receptor expression are decreased in severe asthma. , 2008, American journal of respiratory and critical care medicine.

[5]  H. Schulz,et al.  Dosimetry and toxicology of inhaled ultrafine particles , 2009, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[6]  W. Busse,et al.  Allergy and asthma , 1999, Nature.

[7]  Charles N. Serhan,et al.  Lipid mediator class switching during acute inflammation: signals in resolution , 2001, Nature Immunology.

[8]  P. Helms,et al.  Eosinophil activation and cysteinyl leukotriene production in infants with respiratory syncytial virus bronchiolitis , 2004, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[9]  B. Levy,et al.  Cyclooxygenase 2 Plays a Pivotal Role in the Resolution of Acute Lung Injury1 , 2005, The Journal of Immunology.

[10]  O. Raaschou-Nielsen,et al.  Size distribution and total number concentration of ultrafine and accumulation mode particles and hospital admissions in children and the elderly in Copenhagen, Denmark , 2007, Occupational and Environmental Medicine.

[11]  L. Akinbami,et al.  National surveillance for asthma--United States, 1980-2004. , 2007, Morbidity and mortality weekly report. Surveillance summaries.

[12]  Shinji Takenaka,et al.  Generation of Ultrafine Particles by Spark Discharging , 2004 .

[13]  S. Holgate,et al.  Treatment strategies for allergy and asthma , 2008, Nature Reviews Immunology.

[14]  W. Kreyling,et al.  Ultrafine particle-lung interactions: does size matter? , 2006, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[15]  P. Tiittanen,et al.  Ultrafine particles in urban air and respiratory health among adult asthmatics. , 2001, The European respiratory journal.

[16]  A. Peters,et al.  Short-term effects of particulate air pollution on respiratory morbidity in asthmatic children. , 1997, The European respiratory journal.

[17]  H. Schulz,et al.  Effects of ultrafine carbon particle inhalation on allergic inflammation of the lung. , 2006, The Journal of allergy and clinical immunology.

[18]  J. Heyder,et al.  Oxidative stress and lipid mediators induced in alveolar macrophages by ultrafine particles. , 2005, Free radical biology & medicine.

[19]  E. Karg,et al.  Oxymetazoline Inhibits Proinflammatory Reactions: Effect on Arachidonic Acid-Derived Metabolites , 2006, Journal of Pharmacology and Experimental Therapeutics.

[20]  A. Peters,et al.  Respiratory effects are associated with the number of ultrafine particles. , 1997, American journal of respiratory and critical care medicine.

[21]  G. Oberdörster,et al.  Nanotoxicology: An Emerging Discipline Evolving from Studies of Ultrafine Particles , 2005, Environmental health perspectives.

[22]  L. Palmer,et al.  Diminished lipoxin biosynthesis in severe asthma. , 2005, American journal of respiratory and critical care medicine.

[23]  C. Serhan Resolution phase of inflammation: novel endogenous anti-inflammatory and proresolving lipid mediators and pathways. , 2007, Annual review of immunology.

[24]  C. Denzlinger,et al.  Biology and pathophysiology of leukotrienes. , 1996, Critical reviews in oncology/hematology.

[25]  W. Pierson,et al.  Particulate air pollution and hospital emergency room visits for asthma in Seattle. , 1993, The American review of respiratory disease.

[26]  John Savill,et al.  Resolution of inflammation: the beginning programs the end , 2005, Nature Immunology.

[27]  B. Levy,et al.  Endogenous lipid mediators in the resolution of airway inflammation , 2007, European Respiratory Journal.

[28]  J. Ring,et al.  Effects of Inhaled CdO Particles on the Sphingolipid Synthesis of Rat Lungs , 2003, Inhalation toxicology.

[29]  J. Moreau,et al.  FunctionsIL-10, Which Down-Regulates Dendritic Cell Enhances the Production of Endogenous 2 Cyclooxygenase-2-Issued Prostaglandin E , 2002 .

[30]  E. Israel,et al.  Corticosteroid suppression of lipoxin A4 and leukotriene B4from alveolar macrophages in severe asthma , 2010, Respiratory research.

[31]  Bree L van,et al.  Multiple Path Particle Deposition Model (MPPDep Version 1.11). A model for human and rat airway particle deposition , 1999 .

[32]  H. Schulz,et al.  Effects of ultrafine particles-induced oxidative stress on Clara cells in allergic lung inflammation , 2010, Particle and Fibre Toxicology.

[33]  D. Dockery,et al.  Longitudinal studies of air pollution effects on lung function. , 1996, American journal of respiratory and critical care medicine.

[34]  M. Schladweiler,et al.  Soluble iron modulates iron oxide particle-induced inflammatory responses via prostaglandin E2 synthesis: In vitro and in vivo studies , 2009, Particle and Fibre Toxicology.

[35]  B. Levy,et al.  Resolvins and protectins: mediating solutions to inflammation , 2009, British journal of pharmacology.

[36]  E. Chi,et al.  A role for cysteinyl leukotrienes in airway remodeling in a mouse asthma model. , 2002, American journal of respiratory and critical care medicine.

[37]  Choon-Sik Park,et al.  Blockade of airway inflammation and hyperresponsiveness by inhibition of BLT2, a low-affinity leukotriene B4 receptor. , 2010, American journal of respiratory cell and molecular biology.

[38]  W G Kreyling,et al.  Distribution Pattern of Inhaled Ultrafine Gold Particles in the Rat Lung , 2006, Inhalation toxicology.

[39]  W. Henderson,et al.  Roles of cysteinyl leukotrienes in airway inflammation, smooth muscle function, and remodeling. , 2003, The Journal of allergy and clinical immunology.

[40]  C. Vancheri,et al.  The lung as a privileged site for the beneficial actions of PGE2. , 2004, Trends in immunology.

[41]  E. Karg,et al.  Oxymetazoline Inhibits and Resolves Inflammatory Reactions in Human Neutrophils , 2009, Journal of Pharmacological Sciences.

[42]  J. Heyder,et al.  Agglomerates of ultrafine particles of elemental carbon and TiO2 induce generation of lipid mediators in alveolar macrophages. , 2001, Environmental health perspectives.

[43]  Christopher D. Simpson,et al.  Microstructure and oxidation behaviour of Euro IV diesel engine soot: a comparative study with synthetic model soot substances , 2004 .

[44]  S. Weinbruch,et al.  Transmission electron microscopical and aerosol dynamical characterization of soot aerosols , 2003 .

[45]  B. Levy,et al.  Lipid mediators as agonists for the resolution of acute lung inflammation and injury. , 2007, American journal of respiratory cell and molecular biology.

[46]  Chang-Yu Wu,et al.  Combustion Aerosols: Factors Governing Their Size and Composition and Implications to Human Health , 2000, Journal of the Air & Waste Management Association.

[47]  D. Denis,et al.  The Immunomodulatory Actions of Prostaglandin E2 on Allergic Airway Responses in the Rat1 , 2002, The Journal of Immunology.

[48]  Takao Shimizu,et al.  Lipid mediators in health and disease: enzymes and receptors as therapeutic targets for the regulation of immunity and inflammation. , 2009, Annual review of pharmacology and toxicology.

[49]  R. Phipps,et al.  Prostaglandins as modulators of immunity. , 2002, Trends in immunology.

[50]  C. Brander,et al.  The leukotriene B4 lipid chemoattractant receptor BLT1 defines antigen-primed T cells in humans. , 2006, Blood.